Scleroderma, Systemic: Clinical Trials

41 trials for Scleroderma, Systemic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed. 41 Phase 3, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 341Completed 41
Phase 211Completed 11

Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effectiveness of Cannabinoids on Appetite in Scleroderma
CBD oil, Placebo - Systemic Sclerosis, Malnutrition
Phase 3CompletedKhon Kaen University302022-11-092025-02-20
Rituxmab Versus IL-6 in Treating ILD
Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma
Phase 2 / Phase 3CompletedAssiut University602021-12-012023-11-15
Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis
CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms
Phase 2 / Phase 3CompletedIRCCS San Raffaele162020-05-012024-01-30
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis
Phase 3CompletedCivi Biopharma, Inc.1982019-10-142025-05-25
A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
KHK4827, Placebo - Moderate to Severe Systemic Sclerosis
Phase 3CompletedKyowa Kirin Co., Ltd.1002019-05-232025-07-11
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
BOTOX® solution, Placebo group - Raynaud Phenomenon Secondary to Systemic Sclerosis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris912018-10-152022-02-10
A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis
Phase 2 / Phase 3CompletedTokyo University562017-12-042020-02-18
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Mycophenolate mofetil, Placebo - Systemic Sclerosis, Scleroderma
Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh412016-10-012018-06-06
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
Placebo, Tocilizumab - Systemic Sclerosis
Phase 3CompletedHoffmann-La Roche2122015-11-202020-03-09
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Nintedanib, Placebo - Scleroderma, Systemic
Phase 3CompletedBoehringer Ingelheim5802015-11-122019-12-13
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Onabotulinumtoxin A, sterile saline solution - Scleroderma, Raynaud's Syndrome
Phase 3CompletedJohns Hopkins University402015-01-012016-12-22
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma
Phase 2 / Phase 3CompletedRoyal Brompton & Harefield NHS Foundation Trust1042014-11-012021-10-07
"As Required" Oral Sildenafil in Raynaud's Phenomenon
Sildenafil 40 mg, Sildenafil 80 mg, Placebo - Raynaud's Phenomenon
Phase 2 / Phase 3CompletedUniversity Hospital, Grenoble412013-11-012016-01-18
Gastroesophageal Reflux Treatment in Scleroderma
Alginic acid, placebo (for domperidone), Domperidone - Gastroesophageal Reflux Disease, Systemic Sclerosis
Phase 3CompletedKhon Kaen University802013-06-012017-03-27
Rituximab in Systemic Sclerosis
Rituximab, Placebo (NaCl) - Systemic Sclerosis
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris222013-04-092025-11-20
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Cyclophosphamide, Placebo - Systemic Sclerosis, Scleroderma
Phase 3CompletedAssistance Publique - Hôpitaux de Paris402013-01-142025-09-12
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Placebo, tocilizumab [RoActemra/Actemra] - Sclerosis, Systemic
Phase 3CompletedHoffmann-La Roche872012-03-012016-09-23
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
Tadalafil, Placebo - Lung Diseases, Interstitial
Phase 3CompletedSanjay Gandhi Postgraduate Institute of Medical Sciences402012-03-012015-04-21
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
macitentan 3mg, macitentan 10mg, placebo - Systemic Sclerosis, Ulcers
Phase 3CompletedActelion2892011-12-012015-01-06
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Sildenafil citrate, Placebo (Sugar pill) - Scleroderma, Systemic, Scleroderma, Diffuse
Phase 3CompletedFederal University of São Paulo412011-04-012016-12-05

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Scleroderma, Diffuse (24)  ·  Raynaud Disease (12)  ·  Lung Diseases, Interstitial (6)  ·  Pulmonary Fibrosis (6)  ·  Autoimmune Diseases (5)  ·  digital ulcers (4)  ·  Connective Tissue Diseases (3)  ·  Arthritis (2)  ·  Hypertension, Pulmonary (2)  ·  Myositis (2)  ·  Scleroderma, Limited (2)  ·  Ulcer (2)  ·  Anorexia (1)  ·  Arthritis, Rheumatoid (1)

Broader conditions

Skin Diseases (41)  ·  Skin and Connective Tissue Diseases (41)  ·  Connective Tissue Diseases (38)  ·  Cardiovascular Diseases (14)  ·  Vascular Diseases (14)  ·  Embolism and Thrombosis (12)  ·  Livedoid Vasculopathy (12)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Peripheral Vascular Diseases (12)  ·  Respiratory Tract Diseases (12)  ·  Skin Diseases, Vascular (12)  ·  Thrombosis (12)  ·  Lung Diseases (11)  ·  Pathologic Processes (11)

Interventions

Cyclophosphamide (5)  ·  Bosentan (4)  ·  Nitroglycerin (3)  ·  Rituximab (3)  ·  Sildenafil Citrate (3)  ·  Tadalafil (3)  ·  tocilizumab (3)  ·  Iloprost (2)  ·  Alginic Acid (1)  ·  Botulinum Toxins (1)  ·  Botulinum Toxins, Type A (1)  ·  Domperidone (1)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)  ·  Immunoglobulins, Intravenous (1)  ·  Lidocaine (1)

Sponsors

Actelion (5)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Johns Hopkins University (3)  ·  MediQuest Therapeutics (3)  ·  Sanjay Gandhi Postgraduate Institute of Medical Sciences (3)  ·  Federal University of São Paulo (2)  ·  Hoffmann-La Roche (2)  ·  Khon Kaen University (2)  ·  Allergan (1)  ·  Assiut University (1)  ·  Benesis Corporation (1)  ·  Boehringer Ingelheim (1)  ·  Civi Biopharma, Inc. (1)  ·  Encysive Pharmaceuticals (1)  ·  IRCCS San Raffaele (1)

Countries

United States (13)  ·  France (8)  ·  Canada (6)  ·  India (5)  ·  Japan (5)  ·  United Kingdom (5)  ·  Germany (4)  ·  Italy (4)  ·  Brazil (3)  ·  Denmark (3)  ·  Hungary (3)  ·  Poland (3)  ·  Thailand (3)  ·  Argentina (2)  ·  Australia (2)

Top investigators

Vikas Agarwal, MD, DM (2)  ·  Alexandre WS Silva, PhD (1)  ·  Aman Sharma, MD (1)  ·  Anna Abou-Raya (1)  ·  Ayumi Yoshizaki, MD, PhD (1)  ·  Carin Dugowson, MD, MPH (1)  ·  Chingching Foocharoen, M.D. (1)  ·  Chingching Foocharoen, MD (1)  ·  Daniel E. Furst, MD (1)  ·  Darshan S Bhakuni, MD (1)  ·  Fernando V Andrigueti, MD (1)  ·  Fredrick M Wigley, M.D. (1)

Results publications

PMID 37929840, PMID 33294861, PMID 33765691, PMID 16790698, PMID 17717203, PMID 17901414, PMID 17974598, PMID 18641099, PMID 19892673, PMID 20506355, PMID 20708086, PMID 20800376, PMID 20805294, PMID 20837499, PMID 21547897, PMID 22156609, PMID 23418384, PMID 23910617, PMID 25452309, PMID 25995322, PMID 26704522, PMID 26757749, PMID 27156934, PMID 27163986, PMID 27179107, PMID 28426903, PMID 28544580, PMID 28602891, PMID 28619061, PMID 28664834, PMID 29066464, PMID 29099620, PMID 29298160, PMID 29853453, PMID 29858547, PMID 30383134, PMID 30651141, PMID 31112379, PMID 31813058, PMID 32243207, PMID 32866440, PMID 33131208, PMID 33142016, PMID 33223487, PMID 33328257, PMID 33412120, PMID 33538094, PMID 34533286, PMID 34851799, PMID 35012623

NIH funding

2015 (2), U01HL060839 (1)